Büchner T, Hiddemann W, Zühlsdorf M, Koenigsmann M, Böckmann A, van de Loo J, Schulz G
Dept. Internal Med. University of Münster, W. Germany.
Behring Inst Mitt. 1988 Aug(83):309-12.
In the first clinical study on GM-CSF in acute leukemias continuous infusion of the growth factor is given to patients in aplasia and at high risk of early death due to age over 65 years and/or intensive chemotherapy for resistance or relapse. Among 6 patients (4 AML, 2 ALL) receiving a total of 7 courses two died too early to contributing adequate data. Three patients and 4 courses showed earlier neutrophil recovery than related control groups and a fourth patient with secondary AML showed a neutrophil recovery time in the normal range, but much shorter than her platelet and reticulocyte recovery. No evidence was obtained so far for leukemic regrowth in these patients including blood and bone marrow cytology, monitoring of DNA aneuploidy by flow cytometry and clonogenic cells by colony assays. Thus, GM-CSF may be useful for rescue after intensive chemotherapy of AML and ALL and may not necessarily increase the risk of leukemia progression.
在第一项关于粒细胞-巨噬细胞集落刺激因子（GM-CSF）治疗急性白血病的临床研究中，对于处于再生障碍状态且因年龄超过65岁和/或因耐药或复发接受强化化疗而有早期死亡高风险的患者，给予生长因子持续输注。在总共接受7个疗程治疗的6例患者（4例急性髓系白血病、2例急性淋巴细胞白血病）中，2例过早死亡，未能提供足够数据。3例患者和4个疗程的中性粒细胞恢复较相关对照组更早，第四例继发性急性髓系白血病患者的中性粒细胞恢复时间在正常范围内，但远短于其血小板和网织红细胞的恢复时间。到目前为止，在这些患者中未发现白血病复发的证据，包括血液和骨髓细胞学检查、通过流式细胞术监测DNA非整倍体以及通过集落试验监测克隆形成细胞。因此，GM-CSF可能有助于急性髓系白血病和急性淋巴细胞白血病强化化疗后的挽救治疗，且不一定会增加白血病进展的风险。
